Trial
NCT03505710
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Daiichi Sankyo
Collaborators
Daiichi Sankyo Co., Ltd.; AstraZeneca
Condition
Non-Small Cell Lung Cancer
Intervention
Trastuzumab deruxtecan
Why stopped
Last participant transitioned to alternative study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-05-30